Free Trial

Standard Chartered (STAB) Competitors

GBX 114.20
+0.10 (+0.09%)
(As of 09/13/2024 ET)

STAB vs. BRNS, GWP, SER, ACHL, GKO, HALO, HVE, AZN, GSK, and SOPH

Should you be buying Standard Chartered stock or one of its competitors? The main competitors of Standard Chartered include (BRNS.L) (BRNS), 326553 (GWP.L) (GWP), 5533861 (SER.L) (SER), Asian Citrus (ACHL), Greenko Group (GKO), HaloSource (HALO), Havelock Europa (HVE), AstraZeneca (AZN), GSK (GSK), and Sophos Group plc (SOPH.L) (SOPH). These companies are all part of the "pharmaceutical products" industry.

Standard Chartered vs.

Standard Chartered (LON:STAB) and (BRNS.L) (LON:BRNS) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Standard Chartered had 1 more articles in the media than (BRNS.L). MarketBeat recorded 1 mentions for Standard Chartered and 0 mentions for (BRNS.L). Standard Chartered's average media sentiment score of 0.00 equaled (BRNS.L)'saverage media sentiment score.

Company Overall Sentiment
Standard Chartered Neutral
(BRNS.L) Neutral

Standard Chartered and (BRNS.L) both received 37 outperform votes by MarketBeat users. However, 68.52% of users gave Standard Chartered an outperform vote while only 63.79% of users gave (BRNS.L) an outperform vote.

CompanyUnderperformOutperform
Standard CharteredOutperform Votes
37
68.52%
Underperform Votes
17
31.48%
(BRNS.L)Outperform Votes
37
63.79%
Underperform Votes
21
36.21%

Company Net Margins Return on Equity Return on Assets
Standard CharteredN/A N/A N/A
(BRNS.L) N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard Chartered
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
(BRNS.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Standard CharteredN/AN/AN/AN/AN/A
(BRNS.L)N/AN/AN/AN/AN/A

Summary

Standard Chartered beats (BRNS.L) on 2 of the 2 factors compared between the two stocks.

Get Standard Chartered News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

STAB vs. The Competition

MetricStandard CharteredPharmaceutical Preparations IndustryManufacturing SectorLON Exchange
Market CapN/A£7.42B£1.87B£1.41B
Dividend Yield6.96%4.38%2.68%11.80%
P/E RatioN/A18.6822.721,594.96
Price / SalesN/A248.10482.86178,030.09
Price / CashN/A36.3640.3533.08
Price / BookN/A6.132.432.83
Net IncomeN/A£148.52M£119.72M£151.18M
7 Day PerformanceN/A6.82%16.03%2.56%
1 Month PerformanceN/A11.87%18.31%-1.03%
1 Year PerformanceN/A18.94%12.08%27.45%

Standard Chartered Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRNS
(BRNS.L)
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.00107High Trading Volume
GWP
326553 (GWP.L)
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.00496Gap Up
High Trading Volume
SER
5533861 (SER.L)
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.00N/A
ACHL
Asian Citrus
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.00250High Trading Volume
GKO
Greenko Group
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.0050
HALO
HaloSource
0 of 5 stars
0.00 / 5 stars
GBX 0.25
flat
N/AN/A£0.00N/A0.00390
HVE
Havelock Europa
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£0.00N/A0.00100
AZN
AstraZeneca
1.9069 of 5 stars
1.91 / 5 stars
£120.16
+0.7%
£105.53
-12.2%
+9.0%£186.25B£49.13B3,851.2883,500Insider Buying
News Coverage
GSK
GSK
2.6024 of 5 stars
2.60 / 5 stars
GBX 1,632
-0.1%
GBX 1,805.71
+10.6%
+8.2%£66.59B£31.45B1,444.2590,100
SOPH
Sophos Group plc (SOPH.L)
0 of 5 stars
0.00 / 5 stars
GBX 580.40
+1.0%
N/AN/A£2.99B£726.90M341.41520

Related Companies and Tools

This page (LON:STAB) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners